Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. が 2026年8月3日 に発表した内容

企業自身の 8-K から。

決算説明会

Seaport Therapeutics, Inc. の決算説明会の書き起こしはありません。

経営陣の発言

“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our IPO,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Seaport Therapeutics, Inc. の事業内容

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph TM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.

発表資料の末尾に記載された、企業自身による説明です。